Results 91 to 100 of about 618,942 (290)

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

Classical Hodgkin’s lymphoma shows epigenetic features of abortive plasma cell differentiation

Haematologica, 2011
Background Epigenetic changes are involved in the extinction of the B-cell gene expression program of classical Hodgkin’s lymphoma. However, little is known regarding epigenetic similarities between cells of classical Hodgkin’s lymphoma and plasma cell ...
Volkhard Seitz, Philippe E. Thomas, Karin Zimmermann, Ulrike Paul, Anke Ehlers, Maria Joosten, Lora Dimitrova, Dido Lenze, Anke Sommerfeld, Elisabeth Oker, Ulf Leser, Harald Stein, Michael Hummel   +12 more
doaj   +1 more source

Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.: CYCLON-induced Rituximab resistance [PDF]

, 2013
International audienceImmuno-chemotherapy elicit high response rates in B-cell non-Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refractory disease or relapse.
Alexandra Debernardi, Anouk Emadali, Benoit Bernay, Carlo Petosa, Charles E. McKenna, Christophe Bruley, Claire Rome, Dominique Leroux, Elena Ferri, Florence Combes, Friedberg JW, Juliana Bruder‐Costa, Jérôme Garin, Kato M, Mary B. Callanan, Myriam Ferro, Patricia Betton, Rousseaux S, Rémy Gressin, Saadi Khochbin, Samuel Duley, Sieme Hamaidia, Sophie Rousseaux, Swerdlow SH, Sylvie Kieffer‐Jaquinod   +24 more
core   +4 more sources

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Intravascular large B-cell lymphoma

Przegląd Dermatologiczny, 2021
Agnieszka Odziomek, Piotr Jarliński, Ewelina Rebizak, Jolanta Węgłowska   +3 more
doaj   +1 more source

T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response

Haematologica, 2010
Background Gene expression profiling has successfully identified the prognostic significance of the host response in lymphomas. The aggressive T-cell/histiocyte-rich large B-cell lymphoma and the indolent nodular lymphocyte-predominant Hodgkin’s lymphoma
Peter Van Loo, Thomas Tousseyn, Vera Vanhentenrijk, Daan Dierickx, Agnieszka Malecka, Isabelle Vanden Bempt, Gregor Verhoef, Jan Delabie, Peter Marynen, Patrick Matthys, Chris De Wolf-Peeters   +10 more
doaj   +1 more source

Multicentric B-cell lymphoma in a pygmy goat [PDF]

, 2016
A six-year-old, male pygmy goat was referred with a sudden onset of peripheral lymphadenopathy, which initially started as enlarged inguinal lymph nodes. Clinical examination showed swollen retropharyngeal, prescapular and inguinal lymph nodes. Serologic
Chiers, Koen, Deprez, Piet, Kolkman, Iris, Pardon, Bart, Ribbens, Stefaan, Van Aert, Marcel, Versnaeyen, Han   +6 more
core  

Safety and preliminary efficacy of vorinostat with R-EPOCH in high-risk HIV-associated non-Hodgkin\u27s lymphoma (AMC-075) [PDF]

, 2018
We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma.
Aboulafia, David, Ambinder, Richard F, Cesarman, Ethel, Henry, David, Lee, Jeanette Y, Mitsuyasu, Ronald, Moore, Page C, Noy, Ariela, Ramos, Juan C, Ratner, Lee, Reid, Erin G, Rudek, Michelle A, Sparano, Joseph A   +12 more
core   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma

Hematology Reports, 2011
The determination of prognosis for B-Non- Hodgkin’s lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells.
Hanan Mohamed Mahmoud, Yasmin Nabil Elsakhawy   +1 more
doaj   +1 more source